Sargent Investment Group LLC Acquires 47 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sargent Investment Group LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 711 shares of the medical research company’s stock after buying an additional 47 shares during the quarter. Sargent Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $395,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of TMO. Legacy Investment Solutions LLC acquired a new position in Thermo Fisher Scientific in the 3rd quarter worth about $26,000. Peterson Financial Group Inc. acquired a new position in Thermo Fisher Scientific in the 3rd quarter worth about $27,000. Missouri Trust & Investment Co acquired a new position in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Endeavor Private Wealth Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth about $30,000. Finally, Decker Retirement Planning Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth about $43,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on TMO. Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Raymond James reissued an “outperform” rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday. Robert W. Baird decreased their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Redburn Atlantic started coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $658.00.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,125 shares of company stock valued at $16,207,439 over the last ninety days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Up 0.2 %

TMO stock opened at $581.72 on Thursday. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average is $544.31 and its 200-day moving average is $571.88. The firm has a market capitalization of $222.51 billion, a PE ratio of 35.19, a P/E/G ratio of 4.06 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has initiated a stock buyback plan on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.